Cannapharmarx Stock Market Outlook
| CPMD Stock | USD 0.0049 0.0009 22.50% |
About 52% of CannaPharmaRx's shareholders are presently thinking to get in. The analysis of overall sentiment of trading CannaPharmaRx pink sheet suggests that some market participants are interested at this time. Investor sentiment data for CannaPharmaRx captures the psychological component of price determination that traditional financial metrics miss. Used correctly, it enhances both entry timing and risk control.
Investor Comfort Level 52
Impartial
Panic | Confidence |
Sentiment analytics for CannaPharmaRx matter because the market regularly prices narrative, confidence, and fear alongside operating data. The goal is to add context around perception and momentum, not to replace valuation, earnings, or risk analysis.
News SentimentNeutral | Hype SentimentNeutral | Insider SentimentWaiting |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding CannaPharmaRx is 'Strong Sell'.The recommendation algorithm takes into account all of CannaPharmaRx's available fundamental, technical, and predictive indicators you will find on this site.
Execute CannaPharmaRx Advice
Cross-verify the current analyst consensus on CannaPharmaRx using the CannaPharmaRx recommendation module below. Macroaxis does not own or have any residual interest in CannaPharmaRx or any other equity analyzed by this platform.
Time Horizon
Risk Tolerance
 | Strong Sell |  |
Market Performance | Balanced | Details | |
Volatility | Stable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Small | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
For the selected time horizon CannaPharmaRx has a Mean Deviation of 9.74, Semi Deviation of 7.62, Standard Deviation of 17.14, Variance of 293.8, Downside Variance of 151.34 and Semi Variance of 58.01We provide trade recommendation to complement the right now expert consensus on CannaPharmaRx. Our dynamic recommendation engine employs a multidimensional algorithm to analyze CannaPharmaRx's potential to grow using all technical and fundamental data available right now. To make sure CannaPharmaRx is not overpriced, please confirm all CannaPharmaRx fundamentals, including its the relationship between the book value per share and total asset . As CannaPharmaRx appears to be a penny stock we also suggest to confirm its price to book numbers.
CannaPharmaRx Recent Significant Events and Headlines
CannaPharmaRx Returns Distribution Density
The distribution of CannaPharmaRx's historical returns is an attempt to chart the uncertainty of CannaPharmaRx's future price movements. The chart of the probability distribution of CannaPharmaRx daily returns describes the distribution of returns around its average expected value. We use CannaPharmaRx price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of CannaPharmaRx returns is essential to provide solid investment analysis for CannaPharmaRx.
| Mean Return | 2.47 | Value At Risk | -18.37 | Potential Upside | 25.00 | Standard Deviation | 17.14 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of CannaPharmaRx historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
CannaPharmaRx Greeks
Risk assessment for CannaPharmaRx separates macro-driven volatility from company or sector-specific developments. Market risk cannot be diversified away, though asset-specific exposure can be moderated. CannaPharmaRx (CPMD) recorded a Downside Deviation of 12.30, a Mean Deviation of 9.74, and a Semi Deviation of 7.62.
α | Alpha over Dow Jones | 2.46 | |
β | Beta against Dow Jones | 1.17 | |
σ | Overall volatility | 17.14 | |
Ir | Information ratio | 0.14 |
CannaPharmaRx Volatility Alert
CannaPharmaRx downside-focused statistics highlight the degree of negative price movement. Correlation with broader markets can affect how this instrument behaves inside a diversified portfolio. When assets move together, overall portfolio volatility may increase, while lower correlation can reduce combined risk. Rolling volatility trends help show whether price swings are increasing, stabilizing, or decreasing over time. Periods of expanding volatility may reflect changing market conditions, while contracting volatility may indicate relative stability. Where options markets exist, implied volatility can provide a forward-looking estimate of expected price movement. Overall, volatility analysis combines historical return dispersion, downside deviation, and market structure factors to describe how price movement behaves under current market conditions.CannaPharmaRx Fundamentals Vs Peers
Evaluating CannaPharmaRx's fundamentals in the context of its peer group is a critical step in equity analysis. This comparison helps investors determine whether CannaPharmaRx is generating superior or inferior returns relative to similar pink sheets.
| Better Than Average | Worse Than Average | Compare CannaPharmaRx to competition |
| Fundamentals | CannaPharmaRx | Peer Average |
| Return On Equity | -2.51 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Current Valuation | 20.13 M | 16.62 B |
| Shares Outstanding | 257.57 M | 571.82 M |
| Shares Owned By Insiders | 1.12 % | 10.09 % |
| Price To Book | 11.05 X | 9.51 X |
| EBITDA | -6.07 M | 3.9 B |
| Net Income | -8.83 M | 570.98 M |
| Cash And Equivalents | 5.18 K | 2.7 B |
| Total Debt | 14.96 M | 5.32 B |
| Debt To Equity | 7.05 % | 48.70 % |
| Book Value Per Share | -0.07 X | 1.93 K |
| Cash Flow From Operations | -2.41 M | 971.22 M |
| Earnings Per Share | -0.12 X | 3.12 X |
| Number Of Employees | 4 | 18.84 K |
| Beta | 0.21 | -0.15 |
| Market Capitalization | 2.83 M | 19.03 B |
| Total Asset | 114.33 K | 29.47 B |
| Retained Earnings | -28.64 M | 9.33 B |
| Working Capital | -285 K | 1.48 B |
| Current Asset | 233 K | 9.34 B |
| Current Liabilities | 518 K | 7.9 B |
| Net Asset | 114.33 K |
CannaPharmaRx Market Momentum
A market-strength view of CannaPharmaRx can improve timing discipline by showing how price behavior is evolving beneath the headline move. The better workflow compares strength readings with volatility, trend context, and the broader thesis before acting.
| Accumulation Distribution | 0.33 | |||
| Daily Balance Of Power | 0.5625 | |||
| Rate Of Daily Change | 1.22 | |||
| Day Median Price | 0.0041 | |||
| Day Typical Price | 0.0044 | |||
| Market Facilitation Index | 0.0016 | |||
| Price Action Indicator | 0.0013 | |||
| Period Momentum Indicator | 9.0E-4 | |||
| Relative Strength Index | 57.67 |
Should You Buy or Sell CannaPharmaRx?
The equity advice section for CannaPharmaRx organizes risk-adjusted signals, scenario assumptions, and position-sizing context. This view emphasizes repeatable decision rules over ad hoc reactions to short-term noise. Our framework considers the implications of including CannaPharmaRx in diversified allocations across regimes.
Methodology
Unless otherwise specified, financial data for CannaPharmaRx is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. CannaPharmaRx (USA Stocks:CPMD) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Analyst consensus data and sentiment signals are derived from publicly available research and media sources and reflect a point-in-time view.
Assumptions
Our reporting uses public filings and market reference sources and institutional disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR. Normalization procedures may introduce minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
CannaPharmaRx may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Use Investing Ideas to Build Portfolios
Using CannaPharmaRx inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Did You Try This Idea?
Run Military Industrial Thematic Idea Now
Military Industrial
A collection of large United States defense contractors including companies involved in production or distribution of aircraft, ships, vehicles, weaponry, and electronic systems in cooperation with the government. The Military Industrial theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Military Industrial Theme or any other thematic opportunities.
| View All Next | Launch |
More Resources for CannaPharmaRx Pink Sheet Analysis
Other Information on Investing in CannaPharmaRx Pink Sheet
Financial ratios for CannaPharmaRx help frame valuation context across profits, cash flow, and enterprise value. They help compare CannaPharmaRx across valuation measures and peers.